Indian F&O data, and the evidence about what not to trade · educational
AUROPHARMA · Healthcare
1M / 3M / 1Y
+2.7% / +15.6% / +51.2%
Traded value (60d med)
₹134 cr
Days in F&O ban since 2020
15
Futures OI / 1d change
11.2M / +0.1M
ATM implied vol
25% (vs 24% realized)
📜 Results-day history
Typical move 1.5% · up on the day 59% of 27 events · moved 4%+ in 19% · worst -7.9% / best +7.1%
| Reaction day | Move | Open gap | Next 5d | Announced |
|---|
| 2026-07-21 | +1.3% | +0.5% | -1.9% | after close |
| 2026-04-27 | +0.2% | +0.1% | -2.9% | after close |
| 2026-01-15 | +0.0% | -1.3% | -2.9% | after close |
| 2025-10-17 | -0.5% | -0.0% | -1.5% | during mkt |
| 2025-07-23 | +1.5% | +0.2% | +3.6% | during mkt |
| 2025-04-24 | +0.9% | +0.0% | -3.6% | during mkt |
| 2025-02-07 | -0.0% | -0.6% | -5.1% | after close |
| 2024-11-11 | -2.9% | +0.3% | -3.0% | after close |
Educational data reference: NOT investment advice. Historical statistics do not predict future results. We are not SEBI-registered advisers. All data from NSE public sources; figures may contain errors. Trading, especially leveraged F&O, can cause significant losses.